STOCK TITAN

Edap Tms - EDAP STOCK NEWS

Welcome to our dedicated page for Edap Tms news (Ticker: EDAP), a resource for investors and traders seeking the latest updates and insights on Edap Tms stock.

Company Overview

EDAP TMS SA (NASDAQ: EDAP) is a seasoned global entity focused on the development, manufacturing, promotion, and distribution of minimally-invasive medical devices utilizing advanced therapeutic ultrasound and high-intensity focused ultrasound (HIFU) technologies. With more than three decades of operational history, the company has forged a deep expertise in urological therapies, addressing critical challenges in localized prostate cancer treatment and other urological disorders through innovative, robotic energy-based therapeutic systems.

Innovative Medical Technologies

At its core, EDAP TMS harnesses the potential of therapeutic ultrasound and HIFU to provide patients with precise, minimally-invasive treatment options. The company is architected on a robust portfolio of innovative technologies, backed by a significant patent collection that underscores its commitment to research and development. By integrating advanced imaging with refined treatment modalities, EDAP TMS has set a benchmark in the field of non-surgical therapeutic interventions.

Divisional Expertise and Offerings

EDAP TMS operates through three distinct divisions, each addressing a critical component of the medical device market:

  • HIFU Division: Specializes in developing, manufacturing, and marketing devices that utilize HIFU technology to target and ablate tumors. This division includes a comprehensive range of robotic therapeutic devices that facilitate both invasive and focal treatment options.
  • ESWL Division: Focuses on the engineering and servicing of extracorporeal shockwave lithotripsy systems, providing effective treatment solutions for patients with kidney stones and other related conditions.
  • Distribution Division: Complements the in-house offerings by marketing third-party medical products such as lasers and micro-ultrasound systems, thereby broadening the overall market reach of the company.

Global Market Presence

EDAP TMS has established an extensive global network, operating through corporate offices, subsidiaries, and strategic distribution partnerships across Asia, France, the United States, and other international markets. This diversified geographical reach not only supports robust market penetration but also fosters collaborative clinical research and sharing of best practices in medical device technologies.

Research & Development and Industry Collaborations

The company continually invests in R&D, leveraging partnerships with internationally renowned medical research institutions to drive innovation. This proactive approach has led to the development of its cutting-edge robotic HIFU platforms, including widely recognized solutions for ablation and focal therapy. The integration of imaging advancements with HIFU technology addresses critical needs in minimally-invasive therapies, ensuring that the company's offerings remain at the forefront of medical innovation.

Market Position and Competitive Landscape

EDAP TMS stands out in an increasingly competitive market not only due to its technological prowess but also because of its commitment to quality and regulatory excellence. The clinical credibility embedded in its products is evidenced by rigorous academic collaborations and the publication of peer-reviewed clinical data in prestigious medical journals. While operating within a challenging and tightly regulated industry, the company’s diverse product portfolio and technological innovation serve as key competitive differentiators. Its approach of combining reliable treatment solutions with focused therapy for conditions such as localized prostate cancer provides a solid foundation that appeals to healthcare professionals globally.

Commitment to Quality and Expertise

The operational excellence of EDAP TMS is demonstrated through a disciplined focus on research, development, and quality assurance. The company’s technological infrastructure is built on precision and reliability, ensuring that every device meets the stringent requirements of modern medical practice. Its integrated approach, which connects clinical research with robust manufacturing and distribution strategies, underscores a deep industry expertise that retains credibility across its multiple market segments.

In Summary

Through its pioneering initiatives in robotic and minimally-invasive therapeutic solutions, EDAP TMS SA has cemented its position as a major actor in the field of therapeutic ultrasound and HIFU technology. The company's multi-divisional structure, global outreach, and relentless pursuit of innovation provide an in-depth understanding of the evolving landscape of urological treatment options, contributing to its sustainable role in the medical devices industry.

Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) reports strong Q3 2023 U.S. Focal One® HIFU procedure growth of +150% year-over-year, record nine months HIFU revenues, and a clinical research collaboration with Mount Sinai. The company also placed two additional Focal One systems in the fourth quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.94%
Tags
-
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that CEO Ryan Rhodes will deliver a presentation and host investor meetings at the Jefferies London Healthcare Conference on November 14-16, 2023, in London.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
Rhea-AI Summary
EDAP TMS SA to release Q3 2023 financial results on November 9th and host conference call and webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
Rhea-AI Summary
EDAP TMS SA CEO to present at Morgan Stanley and H.C. Wainwright conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.22%
Tags
conferences
-
Rhea-AI Summary
EDAP TMS reports record Q2 2023 revenues of EUR 14.3 million ($15.5 million) and strong growth in HIFU procedures
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.49%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
conferences
-
Rhea-AI Summary
EDAP TMS SA (Nasdaq: EDAP) announced unaudited financial results for Q1 2023, with total revenue of EUR 14.8 million, a 13.8% increase compared to Q1 2022. The HIFU business revenue increased by 39.5% driven by the sale of six Focal One units. The LITHO business revenue improved due to the sale of four lithotripsy units. The Distribution business revenue decreased slightly. Gross profit margin was 40.8%, lower than the previous year due to investments in service and applications in the U.S. Operating expenses increased significantly to EUR 12.6 million, mainly due to the ongoing build-out of the U.S. team and non-recurring expenses related to the leadership succession plan. The company reported an operating loss of EUR 6.6 million and a net loss of EUR 7.5 million. Cash and cash equivalents were EUR 58.3 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags

FAQ

What is the current stock price of Edap Tms (EDAP)?

The current stock price of Edap Tms (EDAP) is $1.96 as of April 1, 2025.

What is the market cap of Edap Tms (EDAP)?

The market cap of Edap Tms (EDAP) is approximately 72.0M.

What is the core business of EDAP TMS?

EDAP TMS develops, manufactures, promotes, and distributes minimally-invasive medical devices using advanced therapeutic ultrasound and HIFU technology, primarily for urological treatments.

How does EDAP TMS generate revenue?

The company earns revenue through its three operating divisions: HIFU devices for tumor and prostate therapies, ESWL systems for lithotripsy, and the distribution of complementary third-party medical products.

What makes EDAP TMS' HIFU technology unique?

Its HIFU technology is distinguished by the integration of advanced imaging and robotics, offering precision in ablative and focal therapies while maintaining a robust patent portfolio supported by extensive R&D.

In which geographical regions does EDAP TMS operate?

EDAP TMS has a broad international presence with core markets in Asia, France, the United States, and several other global regions, supported by a vast network of corporate offices and distributors.

How does the company support its innovation process?

Continuous investment in R&D, along with strategic collaborations with leading international medical research institutions, defines EDAP TMS' commitment to technological advancement and quality improvement.

What are the main product segments of EDAP TMS?

The company is organized into three divisions: the HIFU division for tumor ablation devices, the ESWL division for lithotripsy systems, and the Distribution division for additional medical products like lasers and micro-ultrasound systems.

How does EDAP TMS ensure the quality and reliability of its devices?

EDAP TMS integrates rigorous quality assurance processes, advanced engineering, and sustained R&D efforts to design devices that meet high industry standards and regulatory requirements.

How does EDAP TMS compare with its competitors in the medical devices industry?

By concentrating on advanced therapeutic ultrasound and HIFU technologies, combined with a diversified product portfolio and strong clinical partnerships, EDAP TMS maintains a distinct position within a competitive landscape.
Edap Tms

Nasdaq:EDAP

EDAP Rankings

EDAP Stock Data

71.98M
37.39M
41.47%
0.11%
Medical Distribution
Healthcare
Link
France
Lyon